| Primary information |
|---|
| sequence ID | Seq_2026 |
| Peptide sequence | EVQLVESGG |
| CancerPDF_ID | CancerPDF_ID9790, CancerPDF_ID11439, |
| PMID | 21533267,26992070 |
| Protein Name | Ig heavy chain V-III region BRO,Ig gamma-1 chain C region |
| UniprotKB Entry Name | HV305_HUMAN,IGHG1_HUMAN |
| Fluid | Serum,Serum |
| M/Z | 459.23,916.45018 |
| Charge | 2,NA |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | LC-MS,LC-MS |
| Peptide Identification technique | LC/MS/MS,LC-MS/MS |
| Quantification Technique | Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | 1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID9790, CancerPDF_ID11439, |
| p-Value | NA,NA |
| Software | MASCOT,SEQUEST and Maxquant |
| Length | 9,9 |
| Cancer Type | Lung adenocarcinoma,Melanoma |
| Database | Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA |
| Number of Patients | 62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." |
| Validation | MRM-based validation of 19 candidates,na |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |